The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.
SLE, a chronic, multisystem autoimmune disorder with a broad range of symptoms, involves defective B cell selection and elimination of self-reactive B cells. B lymphocyte stimulator (BLyS), a soluble ligand of the TNF cytokine family, is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. High levels of BLyS may relax B cell selection and contribute to autoantibody production, exacerbating the SLE disease state. This review discusses the mechanism of BLyS action on B cells, its role in SLE, and specific targeting of BLyS in the treatment of SLE.
Cancro
Michael P
MP
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, 19104-6082, USA. cancro@mail.med.upenn.edu
D'Cruz
David P
DP
Khamashta
Munther A
MA
D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D053264:B-Cell Activating Factor / Q000502:physiology*; D001402:B-Lymphocytes / Q000166:cytology / Q000502:physiology; D002986:Clinical Trials as Topic; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D008954:Models, Biological; D017634:Self Tolerance / Q000502:physiology
D001323:Autoantibodies; D053264:B-Cell Activating Factor